Why do they keep licensing out their tech for next to nothing? 1.9 million in fees? They just received 5 mil, expected to last them through phase 2 clinical trials. Why not license this tech for at LEAST the cost of the later two stages (presumably 5 mil or more)?
If I'm understanding this correctly, I'm disappointed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.